Background {#s1}
==========

Spindle cell carcinoma (SCC) is a highly malignant pulmonary sarcomatoid carcinoma. There is no standard treatment for this disease, though chemotherapy, surgery and radiation therapy may be considered. Here we reported a 58-year-old woman diagnosed with pulmonary SCC who prolonged her survival with the treatment of traditional Chinese medicine (TCM) in China. Due to her overall weak state and financial hardships, she had chosen not to receive surgery, chemotherapy or radiotherapy. TCM was the last option for this patient. After drinking Chinese herbal soup, her tumour has not only remained stable, but her general condition has also improved. To date, this is the longest survival with baseline quality of life of pulmonary SCC, reported in literature.

Case presentation {#s2}
=================

A 58-year-old woman presented with recurrent cough with yellow sputum to a cancer hospital in China in July 2014. Medical history and family history were both negative. Thoracic CT showed a large mass located in her right lung invading the right hilum with ipsilateral mediastinal lymph node enlargement. Pathology from fine-needle aspiration showed pulmonary SCC. Typically, conventional therapies include surgery, chemotherapy and radiotherapy. However, due to her weakened condition and financial hardships, she declined conventional treatment of Western medicine (WM). In October 2014, she reported new symptoms including 38°C fever and intermittent haemoptysis to a TCM hospital in another city. Given her financial constraints, TCM was the only option for this patient. Our TCM physician gave her herbal prescription whose core components consisted of Ma-xing-shi-gan (MXSG) decoction. With this herbal treatment, her fevers abated, her cough improved, and she no longer reported haemoptysis. She kept this herbal treatment for 8 months (150--180 mL orally twice daily). In July 2015, she reported headaches, dizziness and ataxia. A regular head CT and thoracic CT was conducted, indicating a 15.0×13.5×10.0 cm irregular pulmonary mass at the level of aortic arch ([figure 1A,C](#F1){ref-type="fig"}) and low-density lesion in the brainstem. The patient denied further MRI evaluation to verify the brain lesion because of the financial issue. Accordingly, a modified herbal treatment introducing Gastrodiae Rhizoma (GR) and Uncaria Ramulus (UR) (Tian-ma-gou-teng, abbreviated as GRUR) decoction at the basis of MXSG decoction was prescribed to reduce her headaches and dizziness.

![The CT of thorax findings. (A and C) CT in July 2015 showed an irregular low-density mass from the level of right apex (A) to the level of aortic arch, whose size was 15.0×13.5×10.0 cm. (B and D) CT in April 2017 showed stable disease at the level of apex (B) and aortic arch (D), respectively.](bcr-2018-225989f01){#F1}

Outcome and follow-up {#s3}
=====================

In April 2017, imaging assessment ([figure 1B,D](#F1){ref-type="fig"}) revealed stable disease without further progression. More surprisingly, the patient continues to maintain a normal reported baseline quality of life. To date, she is still alive 48 months after the initial diagnosis.

Discussion {#s4}
==========

Pulmonary SCC is a highly malignant variant of carcinoma with histological properties of both epithelial and mesenchymal tumours.[@R1] There is no standard treatment for SCC, though the conventional therapies including surgery, chemotherapy and radiotherapy are commonly used.[@R2] Previous case reports showed poor prognosis and rapid progression of SCC.[@R2] In inoperable cases, platinum-based chemotherapy was selected according to non-small cell carcinoma regimens. Only 3 of 12 patients had a survival of more than 11 months.[@R5] One case reported complete remission of SCC with clinical and radiographical evidence of remission at 42 months, which is the longest survival to date. In this case, the CT of the thorax revealed a 3.5×4.5×6.5 cm hilar mass at the level of aortic arch. The patient had medicated herself with oral germanium sesquioxide after receiving two cycles of chemotherapy followed by radiation.[@R6] Although we report 48-month survival with stable disease (rather than complete remission), our patient received TCM as the monotherapy with extended survival and improvement in her quality of life. Of note, it is also the longest survival with the largest pulmonary SCC tumour burden reported in the literature.

TCM has been widely accepted as a complementary medicine for the management of malignancies, particularly as supportive and palliative care of patients with late-stage cancer.[@R7] Herbal remedies, a major component of TCM, has been used as part of combination therapy or monotherapy to reduce the side effects of chemotherapy.[@R10] Due to the complementary role of TCM in western oncology, TCM physicians have primarily treated patients with late-stage disease. Often, the ultimate goals of management at this stage are to prolong the survival and to better the quality of life, rather than to reduce the tumour burden aggressively. Based on TCM theory of fifth elements and *yinyang*, TCM diagnosis and basal assessment of cancer cannot be fully interpreted in the setting of standard WM system. As this patient declined thorough imaging evaluation with the occurrence of neurological symptoms, it is unclear whether the brain metastases existed or the symptoms resulted from a potential cerebrovascular event. In contrast, per TCM theory, the logical selection of comprehensive herbal formula in each process of disease was made based on 'syndrome differentiation' rather than aetiology of symptoms.[@R11] The initial herbal prescription is composed of mostly MXSG decoction, which includes Ephedrae Herba (EH), Semen Armeniacae Amarum (SAA), Gypsum Fibrosum (GF) and Glycyrrhizae Radix et Rhizoma (GR). MXSG decoction has mainly been used to treat cough, bronchial inflammation and fever from bacterial pneumonia or viral infection in China.[@R12] Among these components, EH and SAA have been individually shown to have anti-inflammatory and immunomodulatory effects on the respiratory system.[@R15] The subsequent treatment, which introduced GR and UR, is indicated for neurodegenerative disease in China.[@R18] Aside from these core components, TCM physicians also added other adjuvant components to enhance the function of core components for this patient. Of note, two components, Hedyotis Diffusa (HD) and Scutellaria Baicalensis (SB), have demonstrated antitumour effects in various types of cancer, including colorectal cancer,[@R21] ovarian cancer,[@R23] pancreatic cancer[@R25] and lung cancer.[@R26] However, there are few studies of these decoctions, as a combination, in the realm of cancer management. Regardless, the TCM regimen helped to improve her symptoms and halt progression of disease.

Clinically and radiographically, our patient has experienced stable disease since undergoing treatment with herbal therapy, a period of 36 months. However, the precise underlying mechanism is unclear. There is increasing evidence that TCM may have a special role in improving the quality of life and potentially prolonging survival of patients with malignancy.[@R9] There remains a need to investigate the potential roles of complementary medicine in the treatment and survival of patients with cancer.

###### Learning points

-   We reported a long-term survival of a patient with pulmonary spindle cell carcinoma (SCC) who underwent treatment with traditional Chinese medicine (TCM) as the monotherapy. Of note, it is the longest survival with largest pulmonary SCC tumour burden reported in the literature.

-   Due to its complementary role in mainstream oncology, TCM may be the last option for patients with late stage disease, which often means that the ultimate goal of management is to prolong survival and to better the quality of life.

-   Based on theoretical differences between Western medicine (WM) and TCM, the choice of herbal prescription cannot be easily understood in the context of modern WM. Yet, the clinical efficacy and potential role of TCM in late-stage malignancy should not be ignored.
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